Skip to main content

Advertisement

SpringerLink
Log in

Neoadjuvant Chemotherapy for Breast Cancer: Does Pretreatment Axillary Nodal Staging Improve Decision Making?

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol. 2008;26(5):791–7. Review.

    Google Scholar 

  2. Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol. 2003;10:718–21.

    Article  PubMed  Google Scholar 

  3. Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol. 2007;4(10):578–90.

    Article  PubMed  CAS  Google Scholar 

  4. Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther. Aug 2005;5(4):737–45.

    Article  PubMed  Google Scholar 

  5. Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357(15):1555–6 author reply 1556.

    Article  PubMed  CAS  Google Scholar 

  6. Kilbride KE, Lee MC, Nees AV, Cimmino VM, Diehl KM, Sabel MS, et al. Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence. Ann Surg Oncol. Nov 2008;15(11):3252–8.

    Article  PubMed  Google Scholar 

  7. Goldhirsch A, Wood WC, Gelber RD,, Coates AS, Thürlimann B, Senn HJ, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer. Ann Surg Oncol. 2007;18(7):1133–44.

    CAS  Google Scholar 

  8. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant(primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18(12):1927–34; Epub 12 Nov 2007. Review.

    Article  PubMed  CAS  Google Scholar 

  9. Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2008;358:197, author reply 198.

    Article  PubMed  CAS  Google Scholar 

  10. Roukos DH. Breast-cancer stromal cells with TP53 mutations. N Engl J Med. 2008;358(15):1636 author reply 1636.

    Google Scholar 

  11. Roukos DH. Linking contralateral breast cancer with genetics. Radiother Oncol. 2008;86:139–41.

    Article  PubMed  Google Scholar 

  12. Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther. 2007;6(3):308–12.

    Article  PubMed  CAS  Google Scholar 

  13. Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol. Jan 2008;15(1):21–33.

    Article  PubMed  Google Scholar 

  14. Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol. 2002;9(10):941–3.

    PubMed  Google Scholar 

  15. Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol. Dec 2004;11(12):1030–4.

    Article  PubMed  Google Scholar 

  16. Ziogas D, Baltogiannis G, Fatouros M, Roukos DH. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg. 2008;247(4):714–5.

    Article  PubMed  Google Scholar 

  17. Liakakos T, Roukos DH. More controversy than ever—challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol. 2008;15(4):956–60.

    Article  PubMed  Google Scholar 

  18. Kappas AM, Roukos DH. Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol. 2002;9(9):828–30.

    Article  PubMed  Google Scholar 

  19. Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol. 2004;11:127–9.

    Article  PubMed  Google Scholar 

  20. Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol. 2007;14:2691–5.

    Article  PubMed  Google Scholar 

  21. Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol. 2002;9:220–1.

    Article  PubMed  Google Scholar 

  22. Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther. 2006;6:931–9.

    Article  PubMed  Google Scholar 

  23. Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest. 2008;118:1590–605.

    Article  PubMed  CAS  Google Scholar 

  24. Roukos DH. Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn. 2008;8(5):587–97.

    Google Scholar 

  25. Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn. 2008;8(1):29–39.

    Article  PubMed  CAS  Google Scholar 

  26. My genome. So, what. Nature. 6 Nov 2008;456(7218):1. Editorial.

    Google Scholar 

  27. Roukos DH. Twenty-One_Gene Assay: challenges and promises in translating personal genomics and whole genome scans into personalized treatment of breast cancer. J Clin Oncol. Epub ahead of print 2 Feb 2009. DOI:10.1200/JCO.2008.20.2812.

  28. Roukos DH, Lykoudis E, Liakakos T. Genomics and challenges toward personalized breast cancer local control. J Clin Oncol. 10 Sep 2008;26(26):4360–1.

    Article  PubMed  Google Scholar 

  29. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456(7218):66–72.

    Article  PubMed  CAS  Google Scholar 

  30. Roukos DH. Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn. Jan 2009;9(1):1–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, School of Medicine, University of Ioannina, Ioannina, Greece

    Charalabos Batsis MD, Dimosthenis Ziogas MD & Michael Fatouros MD

Authors
  1. Charalabos Batsis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dimosthenis Ziogas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Fatouros MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dimosthenis Ziogas MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Batsis, C., Ziogas, D. & Fatouros, M. Neoadjuvant Chemotherapy for Breast Cancer: Does Pretreatment Axillary Nodal Staging Improve Decision Making?. Ann Surg Oncol 16, 1063–1064 (2009). https://doi.org/10.1245/s10434-009-0351-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0351-6

Keywords

Search

Navigation